Article Text

other Versions

PDF
Variation in policies for the management of febrile neutropenia in United Kingdom Children's Cancer Study Group centres
  1. Bob Phillips (bob.phillips{at}doctors.org.uk)
  1. St James's Hospital, United Kingdom
    1. Karen Selwood (karen.selwood{at}rlc.nhs.uk)
    1. Royal Liverpool Chridren's NHS Trust, United Kingdom
      1. Shelia Lane (sheila.lane{at}ubht.nhs.uk)
      1. Bristol Royal Hospital for Children, United Kingdom
        1. Roderick Skinner (roderick.skinner{at}ncl.ac.uk)
        1. Sir James Spence Institute of Child Hlth, United Kingdom
          1. Faith Gibson (gibsof{at}gosh.nhs.uk)
          1. Institute of Child Health, United Kingdom
            1. Julia C Chisholm (chishj{at}gosh.nhs.uk)
            1. Department Paediatric Oncology, United Kingdom

              Abstract

              Objective:To assess the variation in the current UK management strategies for the treatment of febrile neutropenia in childhood.

              Design & Setting:A postal survey of all 21 United Kingdom Children’s Cancer Study Group (UKCCSG) centres assessing and collating local policies, protocols or guidelines relating to the management of febrile neutropenia. Further direct contact was undertaken to clarify any uncertainties.

              Results:All 21 centres provided information. The policies used to manage febrile neutropenia in the centres around the UK vary in almost every aspect of management. Definitions of fever ranged from a persistent temperature of >37.5C to a single reading >39C. Neutropenia was inconsistently defined as an absolute neutrophil count <1 *109 , <0.75 *109 or < 0.5 *109 . Choice of antibiotic approaches, empirical modifications and antistaphylococcal treatment were different in each protocol. The use of risk stratification was undertaken in eleven centres, with six using a policy of reduced intensity therapy in low- risk cases. Empirical antifungal treatment was very poorly described and varied even more widely.

              Conclusions:There was a great deal of variation in definitions and treatment of febrile neutropenia in the UKCCSG children's cancer treatment centres. A degree of variation as a result of local microbiological differences is expected. Beyond this we should seek to standardise the core of our approach: defining fever and neutropenia, risk stratification, and duration of empirical therapy in a way that maintains safety, minimises resource utilisation and maximises quality of life.

              • febrile neutropenia
              • guidelines
              • leukemia
              • paediatric oncology

              Statistics from Altmetric.com

              Request permissions

              If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

              Linked Articles

              • Précis
                BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health
              • Atoms
                Howard Bauchner